Research Article
Carfilzomib Triggers Endoplasmic Reticulum Stress By Up-Regulating the PERK-eIf2α Pathway in Uterine Corpus Endometrial Carcinoma Cells
Author(s):
Zhaozu Feng, Ke Wang, Yunfeng Ma and Wenjuan Luo*
Uterine corpus endometrial carcinoma is one of the most common female pelvic malignancies. Carfilzomib, a second-generation Proteasome Inhibitor (PI), is currently being used for the treatment of multiple myelomas by inhibiting the pathways of IRE1-XBP1 and PERK-eIf2α. However, when used to treat solid tumors, carfilzomib activated the XBP1-IRE1 pathway without affecting PERK-eIf2α. This study aimed to elucidate the function of carfilzomib in UCEC cells and to uncover the influence of PIs on specific cancer cells. Here, two cell lines were treated with carfilzomib, and cell viability, and protein and gene expressions were evaluated. In addition, tumor-carrying BALB/c immunodeficint mice were treated with carfilzomib with or without UMI-77 supplementation, and tumor growth was analyzed. We found that Carfilzomib treatment increased apoptosis and the expression of ER st.. Read More»
10.54608.annalsmedical.2023.83
Select your language of interest to view the total content in your interested language
Annals of Medical and Health Sciences Research received 24805 citations as per google scholar report
The Annals of Medical and Health Sciences Research is a monthly multidisciplinary medical journal.